Affiliation
Navarrabiomed-Fundacion Miguel Servet-Idisna, Complejo Hospitalario de Navarra, Pamplona, SpainIssue Date
2017-10
Metadata
Show full item recordAbstract
The discovery of activating mutations in the serine/threonine (S/T) kinase BRAF followed by a wave of follow-up research manifested that the MAPK-pathway plays a critical role in melanoma initiation and progression. BRAF and MEK inhibitors produce an unparalleled response rate in melanoma, but it is now clear that most responses are transient, and while some patients show long lasting responses the majority progress within 1 year. In accordance with the key role played by the MAPK-pathway in BRAF mutant melanomas, disease progression is mostly due to the appearance of drug-resistance mechanisms leading to restoration of MAPK-pathway activity. In the present article we will review the development, application and clinical effects of BRAF and MEK inhibitors both, as single agent and in combination in the context of targeted therapy in melanoma. We will then describe the most prominent mechanisms of resistance found in patients progressed on these targeted therapies. Finally we will discuss strategies for further optimizing the use of MAPK inhibitors and will describe the potential of alternative combination therapies to either delay the onset of resistance to MAPK inhibitors or directly target specific mechanisms of resistance to BRAF/MEK inhibitors.Citation
Overcoming resistance to BRAF inhibitors. 2017, 5 (19):387 Ann Transl MedJournal
Annals of Translational MedicineDOI
10.21037/atm.2017.06.09PubMed ID
29114545Type
ArticleLanguage
enISSN
2305-5839ae974a485f413a2113503eed53cd6c53
10.21037/atm.2017.06.09
Scopus Count
Collections
Related articles
- Spectrum and Frequency of BRAF Mutations in Skin Melanomas in the Dalmatian Region of Croatia.
- Authors: Bezić J, Tomić I, Pavić M
- Issue date: 2024 Mar
- The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer.
- Authors: Wellbrock C, Arozarena I
- Issue date: 2016
- Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.
- Authors: Rossi A, Roberto M, Panebianco M, Botticelli A, Mazzuca F, Marchetti P
- Issue date: 2019 Nov 5
- MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
- Authors: Rose AA, Annis MG, Frederick DT, Biondini M, Dong Z, Kwong L, Chin L, Keler T, Hawthorne T, Watson IR, Flaherty KT, Siegel PM
- Issue date: 2016 Dec 15
- Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
- Authors: Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M
- Issue date: 2015 Nov 30